Navigation Links
InfuSystem Holdings, Inc. Reports $14.1 Million of Revenues for the Second Quarter of 2012; Announces Annualized Cost Savings in Excess of $1 million

MADISON HEIGHTS, Mich., Aug. 7, 2012 /PRNewswire/ -- InfuSystem Holdings, Inc. (NYSE MKT: INFU) ("InfuSystem" or the "Company"), the leading national provider of infusion pumps and related services for the healthcare industry in the United States, today reported revenues for the quarter ending June 30, 2012, were $14.1 million, up 7% from $13.1 million in the second quarter of 2011.  Total revenues for the six months ended June 30, 2012, were $28.4 million, a 9% improvement from $26.1 million in the 2011 period. 

Gross profit for the three months ending June 30, 2012, was $10.3 million, up 14% from $9.0 million in second quarter of last year.  Gross profit for the first six months of 2012 was $20.7 million, an increase of 15% compared to $18.0 million for the first six months of 2011. 

The second quarter net loss was $0.8 million, equal to a $0.04 loss per diluted share, compared to the $27.9 million net loss, equal to a $1.32 loss per diluted share in the prior period.  For the six months ended June 30, 2012, the Company's net loss was $1.7 million or $0.08 per diluted share, versus a net loss of $28.1 million or $1.33 per diluted share, for the year-ago period.  One-time net expenses of $1.7 million and $3.2 million for the three and six months ended June 30, 2012, hampered these results related, respectively, to the Settlement Agreement and Fifth Amendment, including debt extinguishment, as discussed below. 

The Company achieved a number of annualized cost-savings actions totaling in excess of $1 million in the second quarter, which also saw the installation of a new board and executive management team. 

"We have made important financial and operational progress," said Interim Chief Executive Officer Dilip Singh.  "Eliminating unnecessary management positions and reducing board cash compensation contributed significantly to the $1 million-plus in annual savings.  We expect to see additional cost-saving initiatives introduced in the third quarter.  At the same time, our management team and employees are focused on revenue growth." 

Mr. Singh added that these initial improvements represent the beginning of a broad strategic effort to deliver long-term growth and profitability.  "We will continue to concentrate our efforts on maximizing cash generation with EBITDA for sustained financial stability, while growing market share in our core markets.  Organic growth prospects remain strong.  Feedback from our customers, channels, and partners has been very positive.  They appreciate our commitment to further enhance customer service solutions that make their jobs easier."

Operating Results
The 7% increase in revenues compared to the second quarter of 2011 and the 9% increase for the six months ended June 30, 2012, are primarily related to the addition of new customers with larger patient bases, increased penetration into our existing customer accounts, and the cessation of the 2011 oncology drug shortage affecting certain products.

The $10.3 million in gross profit recorded in the second quarter of 2012 represented 73% of revenues for the current period compared with 68% in the prior year's period. For the first half of 2012, the $20.7 million in gross profit represented 73% of revenues compared to 69% for the same period last year.  This increase in the gross margin percentage was primarily related to lower pump depreciation and a higher mix of pump rentals as compared to pump sales and services.

Selling, general and administrative expenses ("SG&A") for the second quarter of fiscal 2012 were $10.2 million, significantly lower than the prior period's $52.4 million.  For the six months ended June 30, 2012, SG&A was $21.2 million compared with $61.2 million for the same period last year.  The drop in SG&A is due to prior years' numbers contained a charge for asset impairment of $44.2 million.  Excluding non-cash impairment charges, SG&A increased $2.1 million for the quarter and $4.2 million for the six months ended June 30, 2012. 

For the quarter, the major factors contributing to the increase in SG&A were expenses of $1.4 million related primarily to legal fees and $1.0 million of severance costs associated with the Settlement Agreement.  SG&A experienced an increase primarily, compared to the prior periods, in selling compensation and travel costs and an increase in our finance and accounting staffs.  These SG&A costs were partially offset by the reversal of previously recognized stock compensation expense of $1.3 million associated with the Settlement Agreement.  With regard to the first half of 2012, the increase in SG&A related primarily to $2.3 million in legal expenses, the aforementioned $1.0 million in severance costs and $0.6 million in retention payments to key employees – net of the aforementioned $1.3 million reversal of stock compensation expense. The Settlement Agreement is described in the 8-K the Company filed on April 26.  Additional increases in SG&A relate mainly to an increase in selling costs due to higher retention and travel costs.

During the second quarter of fiscal 2012, the Company entered into the Fifth Amendment to its Credit Facility, which resulted in one-time charge for an extinguishment of debt.  Previously capitalized debt issuance costs of $0.3 million and $0.3 million of certain payments made to secure the Fifth Amendment are shown as an extinguishment of debt for the period.

EBITDA for the second quarter of fiscal 2012 was $1.6 million compared with $3.2 million a year ago, excluding asset impairment charges.  For the six months ended June 30, 2012, EBITDA was $3.2 million, compared with $5.6 million for the same period in 2011, excluding asset impairment charges.  Excluding the one-time fees associated with the Settlement Agreement and the Fifth Amendment described above, EBITDA for 2012 would have been $3.3 million and $6.4 million, respectively.  A Non-GAAP reconciliation from net income can be found in the appendix.

Financial Condition
Net cash provided by operations for the six months ended June 30, 2012, was $3.7 million, compared to $2.9 million in the prior-year period.  The latest quarter's results reflected increased professional fees associated with the concerned stockholder group and employee compensation costs.  In addition, the Company reported capital expenditures of $1.7 million, a decrease of $0.7 million compared to the prior-year period.  The Company had available $3.0 million on its $5.0 million revolving credit facility.  During the quarter, the Company reduced its draw under its revolving credit facility by $0.6 million in addition to the normal quarterly payment on its $19.6 million in long-term debt.  The Company ended the quarter with $0.8 million of cash compared to none in the previous quarter.

Conference Call
The Company will host a conference call to share the results of its second quarter fiscal 2012 results on Wednesday, August 8, at 9:00 a.m. Eastern Time. Dilip Singh, Interim Chief Executive Officer, and Jonathan P. Foster, Chief Financial Officer, will discuss the Company's financial performance and answer questions from the financial community.

The Company invites interested investors to listen to the presentation by telephone.  To participate, the dial-in number is (888)-895-5271 with confirmation number 33012557.  Those who wish to listen should dial in five minutes prior to the call to register.  An online audio replay of the conference call will be available on the Company's website for the following 30 days.

About InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc. is the leading provider of infusion pumps and related services to hospitals, oncology practices and other alternate site healthcare providers.  Headquartered in Madison Heights, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, and Ontario, Canada.  The Company's stock is traded on the NYSE MKT under the symbol INFU.

Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements.  These risks and uncertainties include general economic conditions, as well as other risks, detailed from time to time in the Company's publicly filed documents.

Additional information about InfuSystem Holdings, Inc. is available at CONTACT:
Jonathan P. Foster
Chief Financial Officer

CONSOLIDATED BALANCE SHEETSJune 30,December 31,(in thousands, except share data)20122011(Unaudited)ASSETSCurrent Assets:Cash and cash equivalents


799Accounts receivable, less allowance for doubtful accounts of $1,867 and 


7,350$1,773 at June 30, 2012 and December 31, 2011, respectivelyAccounts receivable - related party




3,217Prepaid expenses and other current assets


934Deferred income taxes


682Total Current Assets


13,080Property & equipment, net


15,764Deferred debt issuance costs, net


421Intangible assets, net


28,221Deferred income taxes


18,187Other assets


590Total Assets


LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts payable


4,004Accounts payable - related party


59Derivative liabilities


258Other current liabilities


2,235Current portion of long-term debt


6,576Total Current Liabilities


13,132Revolving credit facility


-Long-term debt, net of current portion


22,551Other liabilities


415Total Liabilities


36,098Stockholders' Equity:Preferred stock, $.0001 par value: authorized 1,000,000 shares; none issued


-Common stock, $.0001 par value; authorized 200,000,000 shares; issued 21,432,161 


2and 21,330,235, respectively; outstanding 21,234,471,and 21,132,545, respectivelyAdditional paid-in capital


87,541Accumulated other comprehensive loss


(136)Accumulated deficit


(47,242)Total Stockholders' Equity


40,165Total Liabilities and Stockholders' Equity



(UNAUDITED)Three Months EndedSix Months EndedJune 30June 30(in thousands, except share data)2012201120122011Net revenues: Rentals

23,019Product Sales

1,0991,6662,5423,071Net revenues

14,07213,13328,42026,090Cost of revenues:Cost of revenues — Product, service and supply costs 

2,1482,1744,3834,316Cost of revenues — Pump depreciation and disposals 

1,6501,9713,3273,732Gross profit 

10,2748,98820,71018,042Selling, general and administrative expenses:Provision for doubtful accounts 

8939272,1402,149Amortization of intangibles 

6746631,3581,309Asset impairment charges 

-44,213-44,213Selling and marketing 

2,5412,3265,2864,769General and administrative 

6,1374,25112,4108,767Total sales, general and administrative

10,24552,38021,19461,207Operating income (loss)

29(43,392)(484)(43,165)Other income (expense):Gain on derivatives 

-83-83Interest expense 

(663)(564)(1,264)(1,105)Loss on extinguishment of long term debt 

(552)-(552)-Other income 

-22-Total other loss 

(1,215)(479)(1,814)(1,022)Loss before income taxes 

(1,186)(43,871)(2,298)(44,187)Income tax benefit 

35815,98555516,131Net loss

Net loss per share:Basic 


(0.04)(1.32)(0.08)(1.33)Weighted average shares outstanding:Basic 


21,196,08521,059,29221,164,31521,080,683Comprehensive LossNet loss

(28,056)Unrealized (loss) gain on interest rate swap, net of taxes

-(81)1(34)Reclassification of hedging losses, net of taxes

(111)-(111)-Comprehensive Loss

(UNAUDITED)Six Months EndedJune 30(in thousands)20122011OPERATING ACTIVITIESNet loss


$   (28,056)Adjustments to reconcile net loss to net cash provided by operating activities:Loss on cash flow hedge


-Gain on derivative liabilities 


(83)Loss on extinguishment of long-term debt 


-Provision for doubtful accounts 




3,167Amortization of intangible assets 


1,309Asset impairment charges 


44,213Amortization of deferred debt issuance costs 


122Stock-based compensation 


502Deferred income taxes 


(16,242)Changes in assets - (Increase)/Decrease:Accounts receivable, net of provision




794Other current assets


67Other assets


(166)Changes in liabilities - Increase/(Decrease):Accounts payable and other liabilities 



2,928INVESTING ACTIVITIESCapital expenditures 


(2,383)Other asset acquisitions



(3,325)FINANCING ACTIVITIESPrincipal payments on debt


(2,061)Proceeds from draw on revolving credit facility


-Common stock repurchased to satisfy statutory witholding on stock based compensation 


-Treasury shares repurchased 


(248)Principal payments on capital lease obligations 



(2,894)Net change in cash and cash equivalents 5

(3,291)Cash and cash equivalents, beginning of period 799

5,014Cash and cash equivalents, end of period $


(UNAUDITED)Three Months EndedSix Months EndedJune 30June 30(in thousands, except share data)2012201120122011Net loss

(28,056)Adjustments:  Interest expense

6635641,2641,105  Income tax benefit

(358)(15,985)(555)(16,131)  Depreciation

1,4581,6092,9033,167  Amortization



SOURCE InfuSystem Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. InfuSystem Holdings, Inc. To Announce First Quarter 2012 Financial Results On May 21, 2012
2. InfuSystem Holdings, Inc. Receives Letter From NYSE MKT Regarding Timely Notice Of Record Date For 2012 Annual Meeting Of Stockholders
3. InfuSystem Holdings, Inc. Reports $14.3 Million of Revenues And $1.6 Million Of EBITDA For The First Quarter Of 2012
4. InfuSystem Holdings Modifies Bylaws to Align with Corporate Governance Best Practices
5. InfuSystem Holdings, Inc. Terminates "Poison Pill" Plan
6. China Pharma Holdings, Inc. Reports First Quarter 2012 Financial Results
7. Hill-Rom Holdings, Inc. Hosts Fiscal 2012 Third Quarter Earnings Conference Call and Webcast
8. RoundTable Healthcare Partners Portfolio Company, Renaissance Acquisition Holdings, LLC Acquires DPT Laboratories
9. Ultra Clean Holdings, Inc. Completes Strategic Merger with Advanced Integration Technologies
10. RoundTable Healthcare Partners Announces Sale of Aspen Surgical Products Holding, Inc. to Hill-Rom Holdings, Inc.
11. Bacterin International Holdings, Inc. Schedules Second Quarter 2012 Financial Earnings Conference Call
Post Your Comments:
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):